MacroGenics has announced the discontinuation of its PD-1xCTLA-4 bispecific antibody, lorigerlimab, which was under investigation for prostate cancer treatment. This decision comes after an evaluation of the drug’s clinical potential and market viability, marking a significant pivot in the company’s oncology portfolio strategy.
The halt in development reflects broader challenges within the bispecific antibody landscape, where competition is intensifying and clinical outcomes are under scrutiny. MacroGenics’ move may signal a shift in focus towards more promising therapeutic candidates or alternative mechanisms of action, as the company reassesses its pipeline in light of recent clinical data and market dynamics.
In a related development, Third Arc Bio has entered into a collaboration with Adagene, aiming to leverage Adagene’s proprietary technology to enhance antibody development. This partnership underscores the ongoing trend of strategic alliances in the biopharmaceutical sector, as companies seek to optimize their R&D efforts and expand their therapeutic offerings in an increasingly competitive environment.
Use the database as your supply chain compass →
